Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

14/12/2018 The Open Innovation Forum matches business challenges to academic solutions 07/12/2018 2017 BioCat report: The best of the Bioregion of Catalonia 30/11/2018 Barcelona Synchrotron Park’s Commitment to Sustainable Growth 23/11/2018 Astronomers led by IEEC reveal a cold super-Earth around Barnard’s star 16/11/2018 CRAG’s Researchers discover how to generate plants with enhanced drought resistance 08/11/2018 The Barcelona manifesto: for a city-led science and technology diplomacy
6 7 8 9 10 11 12 13 14 15 16